Article(id=1330228319733264492, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228319234142315, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.08.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1644681600000, receivedDateStr=2022-02-13, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080745870, onlineDateStr=2026-11-19, pubDate=1660060800000, pubDateStr=2022-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080745870, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080745870, creator=13701087609, updateTime=1795080745870, updator=13701087609, issue=Issue{id=1330228319234142315, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='8', pageStart='961', pageEnd='1066', issueExtLink='null', onlineDate='null', pubDate='1660060800000', pubDateStr='2022-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080745752, creator='13701087609', updateTime=1795084770606, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330245201056084694, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228319234142315, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330245201056084695, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228319234142315, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=961, endPage=966, ext={EN=ArticleExt(id=1330228319926202477, articleId=1330228319733264492, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances in chimeric antigen receptor therapy for T cell malignant tumors, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

T-cell malignant tumors are characterized by high malignancy and poor prognosis. Hematopoietic stem cell transplantation is the most effective treatment approach in relapsed or refractory T-cell malignancies, which is often accompanied by severe transplantation-associated complications. Therefore, it is urgent to explore safe and effective therapies. Chimeric antigen receptor T cell therapy (CAR-T cell therapy), as a relatively novel immunotherapy method, has achieved great clinical benefits in relapsed or refractory B cell malignant tumor and multiple myeloma. Up to now, eight related drugs have been approved (6 approved by FDA and 8 approved by CFDA). However, for T-cell malignant tumors, CAR-T cell immunotherapy is still in the stages of preclinical and (or) early clinical, and faces many difficulties and challenges. This article reviewed the current research progress of CAR-T cell therapy for T cell malignancies.

, authors=Xiaochen WU1, Shan HE2, Jun LU1, *, authorsList=Xiaochen WU, Shan HE, Jun LU, authorCompany=null, correspAuthors=Jun LU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330228320148500590, articleId=1330228319733264492, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=T细胞恶性肿瘤的嵌合抗原受体T细胞治疗研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

T细胞恶性肿瘤具有高度恶性、预后差等特点,对于复发/难治性患者当前最有效的治疗手段是造血干细胞移植,但往往伴随着诸多移植相关风险,故探索更多安全、有效的疗法迫在眉睫。嵌合抗原受体T细胞治疗(chimeric antigen receptor T cell therapy,CAR-T cell therapy)作为一种近年来较新颖的免疫疗法,在复发/难治性B细胞恶性肿瘤及多发性骨髓瘤中已展现出了巨大临床受益。然而对于T细胞恶性肿瘤,CAR-T细胞治疗仍处于临床前和早期临床阶段,并面临着重重困难。现阐述目前T细胞恶性肿瘤的CAR-T细胞治疗的研究进展,旨在为临床治疗相关疾病提供一定参考。

, authors=吴晓晨1, 何珊2, 卢俊1, *, authorsList=吴晓晨, 何珊, 卢俊, authorCompany=null, correspAuthors=卢俊, authorNote=

吴晓晨,硕士研究生,研究方向:儿童血液肿瘤。

, correspAuthorsNote=
卢俊,主任医师,研究方向:儿童血液肿瘤。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=kHxz0V9SsFxrc8nenz70Ew==, magXml=+QHmRwGCQFPxFsq0VJ+4lw==, pdfUrl=null, pdf=PWaAJRJwjFciWB0Kx7vYLg==, pdfFileSize=1651595, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=4kC7tjcIp+wH0rHKqq5eRQ==, mapNumber=null, fund=null)}, authors=[Author(id=1330228320500822134, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228320580513912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320500822134, language=EN, stringName=Xiaochen WU, firstName=Xiaochen, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228320643428473, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320500822134, language=CN, stringName=吴晓晨, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.苏州大学附属儿童医院血液科,江苏 苏州 215002, bio={"content":"

吴晓晨,硕士研究生,研究方向:儿童血液肿瘤。

"}, bioImg=null, bioContent=

吴晓晨,硕士研究生,研究方向:儿童血液肿瘤。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228320341438575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, xref=1., ext=[AuthorCompanyExt(id=1330228320349827184, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China), AuthorCompanyExt(id=1330228320358215793, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.苏州大学附属儿童医院血液科,江苏 苏州 215002)])]), Author(id=1330228320706343035, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228320781840509, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320706343035, language=EN, stringName=Shan HE, firstName=Shan, middleName=null, lastName=HE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Vitalgen Biopharma, Shanghai 201210, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228320857337982, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320706343035, language=CN, stringName=何珊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海天泽云泰生物医药有限公司,上海 201210, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228320421130354, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, xref=2., ext=[AuthorCompanyExt(id=1330228320425324659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320421130354, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Vitalgen Biopharma, Shanghai 201210, China), AuthorCompanyExt(id=1330228320433713268, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320421130354, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海天泽云泰生物医药有限公司,上海 201210)])]), Author(id=1330228320916058240, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330228320991555714, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320916058240, language=EN, stringName=Jun LU, firstName=Jun, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228321058664579, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320916058240, language=CN, stringName=卢俊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.苏州大学附属儿童医院血液科,江苏 苏州 215002, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228320341438575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, xref=1., ext=[AuthorCompanyExt(id=1330228320349827184, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China), AuthorCompanyExt(id=1330228320358215793, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.苏州大学附属儿童医院血液科,江苏 苏州 215002)])])], keywords=[Keyword(id=1330228321155133572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, language=EN, orderNo=1, keyword=T cell malignant tumor), Keyword(id=1330228321226436741, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, language=EN, orderNo=2, keyword=chimeric antigen receptor therapy (CAR-T)), Keyword(id=1330228321280962694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, language=EN, orderNo=3, keyword=chimeric antigen receptor natural killer cell), Keyword(id=1330228321352265863, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, language=EN, orderNo=4, keyword=T cell regeneration disorder), Keyword(id=1330228321410986120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, language=CN, orderNo=1, keyword=T细胞恶性肿瘤), Keyword(id=1330228321473900681, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, language=CN, orderNo=2, keyword=嵌合抗原受体T细胞治疗), Keyword(id=1330228321549398154, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, language=CN, orderNo=3, keyword=嵌合抗原受体自然杀伤细胞), Keyword(id=1330228321616507019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, language=CN, orderNo=4, keyword=T细胞再生障碍)], refs=[Reference(id=1330228321809445005, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Lamble AJ, Gardner R. CAR T cells for other pediatric non-B-cell hematologic malignancies[J]. Hematology Am Soc Hematol Educ Program, 2020, 2020(1): 494-500., articleTitle=null, refAbstract=null), Reference(id=1330228323420057742, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Safarzadeh Kozani P, Safarzadeh Kozani P, O'Connor RS. In like a lamb; Out like a lion: marching CAR T cells toward enhanced efficacy in B-ALL[J]. Mol Cancer Ther, 2021, 20(7): 1223-1233., articleTitle=null, refAbstract=null), Reference(id=1330228323503943823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang C, Liu J, Zhong JF, et al. Engineering CAR-T cells[J]. Biomark Res, 2017, 5: 22., articleTitle=null, refAbstract=null), Reference(id=1330228323579441296, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Hashem Boroojerdi M, Rahbarizadeh F, Safarzadeh Kozani P, et al. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia[J]. Med Oncol, 2020, 37(11): 100., articleTitle=null, refAbstract=null), Reference(id=1330228323663327377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Xie G, Dong H, Liang Y, et al. CAR-NK cells: a promising cellular immunotherapy for cancer[J]. EBioMedicine, 2020, 59: 102975., articleTitle=null, refAbstract=null), Reference(id=1330228323755602066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells[J]. Br J Cancer, 2019, 120(1): 26-37., articleTitle=null, refAbstract=null), Reference(id=1330228323831099539, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy[J]. Biochem Soc Trans, 2016, 44(2): 412-418., articleTitle=null, refAbstract=null), Reference(id=1330228323919179924, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao J, Lin Q, Song Y, et al. Universal CARs, universal T cells, and universal CAR T cells[J]. J Hematol Oncol, 2018, 11(1): 132., articleTitle=null, refAbstract=null), Reference(id=1330228323986288789, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Azzam HS, Grinberg A, Lui K, et al. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity[J]. J Exp Med, 1998, 188(12): 2301-2311., articleTitle=null, refAbstract=null), Reference(id=1330228324074369174, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Mamonkin M, Rouce RH, Tashiro H, et al. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies[J]. Blood, 2015, 126(8): 983-992., articleTitle=null, refAbstract=null), Reference(id=1330228324145672343, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Sempowski GD, Lee DM, Kaufman RE, et al. Structure and function of the CD7 molecule[J]. Crit Rev Immunol, 1999, 19(4): 331-348., articleTitle=null, refAbstract=null), Reference(id=1330228324204392601, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Kim MY, Cooper ML, Jacobs MT, et al. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy[J]. JCI Insight, 2021, 6(16): e149819., articleTitle=null, refAbstract=null), Reference(id=1330228324271501466, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Cooper ML, Dipersio JF. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies[J]. Best Pract Res Clin Haematol, 2019, 32(4): 101097., articleTitle=null, refAbstract=null), Reference(id=1330228324346998939, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen D, You F, Xiang S, et al. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies[J]. Am J Cancer Res, 2021, 11(11): 5263-5281., articleTitle=null, refAbstract=null), Reference(id=1330228324418302108, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang M, Chen D, Fu X, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma[J]. Clin Cancer Res, 2022, 28(13): 2830-2843., articleTitle=null, refAbstract=null), Reference(id=1330228324468633757, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Frankel AE, Zuckero SL, Mankin AA, et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma[J]. Curr Drug Targets, 2009, 10(2): 104-109., articleTitle=null, refAbstract=null), Reference(id=1330228324531548318, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen KH, Wada M, Firor AE, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies[J]. Oncotarget, 2016, 7(35): 56219-56232., articleTitle=null, refAbstract=null), Reference(id=1330228324590268575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Maciocia PM, Wawrzyniecka PA, Philip B, et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies[J]. Nat Med, 2017, 23(12): 1416-1423., articleTitle=null, refAbstract=null), Reference(id=1330228324653183136, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Yilmaz A, Cui H, Caligiuri MA, et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy[J]. J Hematol Oncol, 2020, 13(1): 168., articleTitle=null, refAbstract=null), Reference(id=1330228324728680609, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Marofi F, Abdul-Rasheed OF, Rahman HS, et al. CAR-NK cell in cancer immunotherapy; A promising frontier[J]. Cancer Sci, 2021, 112(9): 3427-3436., articleTitle=null, refAbstract=null), Reference(id=1330228324799983778, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors[J]. N Engl J Med, 2020, 382(6): 545-553., articleTitle=null, refAbstract=null), Reference(id=1330228324867092643, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Rezvani K, Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer[J]. Front Immunol, 2015, 6: 578., articleTitle=null, refAbstract=null), Reference(id=1330228324938395812, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit?[J]. Stem Cell Res Ther, 2021, 12(1): 527., articleTitle=null, refAbstract=null), Reference(id=1330228325001310373, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Jones BS, Lamb LS, Goldman F, et al. Improving the safety of cell therapy products by suicide gene transfer[J]. Front Pharmacol, 2014, 5: 254., articleTitle=null, refAbstract=null), Reference(id=1330228325068419238, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, et al. Strategies for dodging the obstacles in CAR T cell therapy[J]. Front Oncol, 2021, 11: 627549., articleTitle=null, refAbstract=null), Reference(id=1330228325135528103, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Marin V, Cribioli E, Philip B, et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells[J]. Hum Gene Ther Methods, 2012, 23(6): 376-386., articleTitle=null, refAbstract=null), Reference(id=1330228325231997096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy[J]. N Engl J Med, 2011, 365(18): 1673-1683., articleTitle=null, refAbstract=null), Reference(id=1330228325315883177, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Gomes-Silva D, Srinivasan M, Sharma S, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies[J]. Blood, 2017, 130(3): 285-296., articleTitle=null, refAbstract=null), Reference(id=1330228325374603434, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Cooper ML, Choi J, Staser K, et al. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies[J]. Leukemia, 2018, 32(9): 1970-1983., articleTitle=null, refAbstract=null), Reference(id=1330228325437517995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Png YT, Vinanica N, Kamiya T, et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies[J]. Blood Adv, 2017, 1(25): 2348-2360., articleTitle=null, refAbstract=null), Reference(id=1330228325496238252, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen KH, Wada M, Pinz KG, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor[J]. Leukemia, 2017, 31(10): 2151-2160., articleTitle=null, refAbstract=null), Reference(id=1330228325563347117, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=You F, Wang Y, Jiang L, et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia[J]. Am J Cancer Res, 2019, 9(1): 64-78., articleTitle=null, refAbstract=null)], funds=[Fund(id=1330228321721364620, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, awardId=ZD2021006, language=CN, fundingSource=江苏省卫生健康委员会基金项目(ZD2021006), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1330228320341438575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, xref=1., ext=[AuthorCompanyExt(id=1330228320349827184, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China), AuthorCompanyExt(id=1330228320358215793, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.苏州大学附属儿童医院血液科,江苏 苏州 215002)]), AuthorCompany(id=1330228320421130354, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, xref=2., ext=[AuthorCompanyExt(id=1330228320425324659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320421130354, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Vitalgen Biopharma, Shanghai 201210, China), AuthorCompanyExt(id=1330228320433713268, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320421130354, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海天泽云泰生物医药有限公司,上海 201210)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.08.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.08.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.08.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.08.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1660060800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
T细胞恶性肿瘤的嵌合抗原受体T细胞治疗研究进展
吴晓晨 1 , 何珊 2 , 卢俊 1, *
世界临床药物 | 医药专论 2022,43(8): 961-966
收起
收藏切换
世界临床药物 |医药专论 2022 , 43 (8) : 961 -966
T细胞恶性肿瘤的嵌合抗原受体T细胞治疗研究进展
全屏
[Author(id=1330228320500822134, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228320580513912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320500822134, language=EN, stringName=Xiaochen WU, firstName=Xiaochen, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228320643428473, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320500822134, language=CN, stringName=吴晓晨, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.苏州大学附属儿童医院血液科,江苏 苏州 215002, bio={"content":"

吴晓晨,硕士研究生,研究方向:儿童血液肿瘤。

"}, bioImg=null, bioContent=

吴晓晨,硕士研究生,研究方向:儿童血液肿瘤。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228320341438575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, xref=1., ext=[AuthorCompanyExt(id=1330228320349827184, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China), AuthorCompanyExt(id=1330228320358215793, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.苏州大学附属儿童医院血液科,江苏 苏州 215002)])]), Author(id=1330228320706343035, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228320781840509, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320706343035, language=EN, stringName=Shan HE, firstName=Shan, middleName=null, lastName=HE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Vitalgen Biopharma, Shanghai 201210, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228320857337982, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320706343035, language=CN, stringName=何珊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海天泽云泰生物医药有限公司,上海 201210, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228320421130354, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, xref=2., ext=[AuthorCompanyExt(id=1330228320425324659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320421130354, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Vitalgen Biopharma, Shanghai 201210, China), AuthorCompanyExt(id=1330228320433713268, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320421130354, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海天泽云泰生物医药有限公司,上海 201210)])]), Author(id=1330228320916058240, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330228320991555714, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320916058240, language=EN, stringName=Jun LU, firstName=Jun, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228321058664579, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, authorId=1330228320916058240, language=CN, stringName=卢俊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.苏州大学附属儿童医院血液科,江苏 苏州 215002, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228320341438575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, xref=1., ext=[AuthorCompanyExt(id=1330228320349827184, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China), AuthorCompanyExt(id=1330228320358215793, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228319733264492, companyId=1330228320341438575, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.苏州大学附属儿童医院血液科,江苏 苏州 215002)])])]
吴晓晨1, 何珊2, 卢俊1, *
作者信息
  • 1.苏州大学附属儿童医院血液科,江苏 苏州 215002
  • 2.上海天泽云泰生物医药有限公司,上海 201210
通讯作者:
卢俊,主任医师,研究方向:儿童血液肿瘤。
作者简介:

吴晓晨,硕士研究生,研究方向:儿童血液肿瘤。

Advances in chimeric antigen receptor therapy for T cell malignant tumors
Xiaochen WU1, Shan HE2, Jun LU1, *
Affiliations
  • 1.Department of Hematology, Children's Hospital of Soochow University, Suzhou 215002, Jiangsu Province, China
  • 2.Vitalgen Biopharma, Shanghai 201210, China
出版时间: 2022-08-10 doi: 10.13683/j.wph.2022.08.001
文章导航
收藏切换

T细胞恶性肿瘤具有高度恶性、预后差等特点,对于复发/难治性患者当前最有效的治疗手段是造血干细胞移植,但往往伴随着诸多移植相关风险,故探索更多安全、有效的疗法迫在眉睫。嵌合抗原受体T细胞治疗(chimeric antigen receptor T cell therapy,CAR-T cell therapy)作为一种近年来较新颖的免疫疗法,在复发/难治性B细胞恶性肿瘤及多发性骨髓瘤中已展现出了巨大临床受益。然而对于T细胞恶性肿瘤,CAR-T细胞治疗仍处于临床前和早期临床阶段,并面临着重重困难。现阐述目前T细胞恶性肿瘤的CAR-T细胞治疗的研究进展,旨在为临床治疗相关疾病提供一定参考。

T细胞恶性肿瘤  /  嵌合抗原受体T细胞治疗  /  嵌合抗原受体自然杀伤细胞  /  T细胞再生障碍

T-cell malignant tumors are characterized by high malignancy and poor prognosis. Hematopoietic stem cell transplantation is the most effective treatment approach in relapsed or refractory T-cell malignancies, which is often accompanied by severe transplantation-associated complications. Therefore, it is urgent to explore safe and effective therapies. Chimeric antigen receptor T cell therapy (CAR-T cell therapy), as a relatively novel immunotherapy method, has achieved great clinical benefits in relapsed or refractory B cell malignant tumor and multiple myeloma. Up to now, eight related drugs have been approved (6 approved by FDA and 8 approved by CFDA). However, for T-cell malignant tumors, CAR-T cell immunotherapy is still in the stages of preclinical and (or) early clinical, and faces many difficulties and challenges. This article reviewed the current research progress of CAR-T cell therapy for T cell malignancies.

T cell malignant tumor  /  chimeric antigen receptor therapy (CAR-T)  /  chimeric antigen receptor natural killer cell  /  T cell regeneration disorder
吴晓晨, 何珊, 卢俊. T细胞恶性肿瘤的嵌合抗原受体T细胞治疗研究进展. 世界临床药物, 2022 , 43 (8) : 961 -966 . DOI: 10.13683/j.wph.2022.08.001
Xiaochen WU, Shan HE, Jun LU. Advances in chimeric antigen receptor therapy for T cell malignant tumors[J]. World Clinical Drug, 2022 , 43 (8) : 961 -966 . DOI: 10.13683/j.wph.2022.08.001
  • 江苏省卫生健康委员会基金项目(ZD2021006)
参考文献 引证文献
排序方式:
[1]
Lamble AJ, Gardner R. CAR T cells for other pediatric non-B-cell hematologic malignancies[J]. Hematology Am Soc Hematol Educ Program, 2020, 2020(1): 494-500.
[2]
Safarzadeh Kozani P, Safarzadeh Kozani P, O'Connor RS. In like a lamb; Out like a lion: marching CAR T cells toward enhanced efficacy in B-ALL[J]. Mol Cancer Ther, 2021, 20(7): 1223-1233.
[3]
Zhang C, Liu J, Zhong JF, et al. Engineering CAR-T cells[J]. Biomark Res, 2017, 5: 22.
[4]
Hashem Boroojerdi M, Rahbarizadeh F, Safarzadeh Kozani P, et al. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia[J]. Med Oncol, 2020, 37(11): 100.
[5]
Xie G, Dong H, Liang Y, et al. CAR-NK cells: a promising cellular immunotherapy for cancer[J]. EBioMedicine, 2020, 59: 102975.
[6]
Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells[J]. Br J Cancer, 2019, 120(1): 26-37.
[7]
Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy[J]. Biochem Soc Trans, 2016, 44(2): 412-418.
[8]
Zhao J, Lin Q, Song Y, et al. Universal CARs, universal T cells, and universal CAR T cells[J]. J Hematol Oncol, 2018, 11(1): 132.
[9]
Azzam HS, Grinberg A, Lui K, et al. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity[J]. J Exp Med, 1998, 188(12): 2301-2311.
[10]
Mamonkin M, Rouce RH, Tashiro H, et al. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies[J]. Blood, 2015, 126(8): 983-992.
[11]
Sempowski GD, Lee DM, Kaufman RE, et al. Structure and function of the CD7 molecule[J]. Crit Rev Immunol, 1999, 19(4): 331-348.
[12]
Kim MY, Cooper ML, Jacobs MT, et al. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy[J]. JCI Insight, 2021, 6(16): e149819.
[13]
Cooper ML, Dipersio JF. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies[J]. Best Pract Res Clin Haematol, 2019, 32(4): 101097.
[14]
Chen D, You F, Xiang S, et al. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies[J]. Am J Cancer Res, 2021, 11(11): 5263-5281.
[15]
Zhang M, Chen D, Fu X, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma[J]. Clin Cancer Res, 2022, 28(13): 2830-2843.
[16]
Frankel AE, Zuckero SL, Mankin AA, et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma[J]. Curr Drug Targets, 2009, 10(2): 104-109.
[17]
Chen KH, Wada M, Firor AE, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies[J]. Oncotarget, 2016, 7(35): 56219-56232.
[18]
Maciocia PM, Wawrzyniecka PA, Philip B, et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies[J]. Nat Med, 2017, 23(12): 1416-1423.
[19]
Yilmaz A, Cui H, Caligiuri MA, et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy[J]. J Hematol Oncol, 2020, 13(1): 168.
[20]
Marofi F, Abdul-Rasheed OF, Rahman HS, et al. CAR-NK cell in cancer immunotherapy; A promising frontier[J]. Cancer Sci, 2021, 112(9): 3427-3436.
[21]
Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors[J]. N Engl J Med, 2020, 382(6): 545-553.
[22]
Rezvani K, Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer[J]. Front Immunol, 2015, 6: 578.
[23]
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit?[J]. Stem Cell Res Ther, 2021, 12(1): 527.
[24]
Jones BS, Lamb LS, Goldman F, et al. Improving the safety of cell therapy products by suicide gene transfer[J]. Front Pharmacol, 2014, 5: 254.
[25]
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, et al. Strategies for dodging the obstacles in CAR T cell therapy[J]. Front Oncol, 2021, 11: 627549.
[26]
Marin V, Cribioli E, Philip B, et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells[J]. Hum Gene Ther Methods, 2012, 23(6): 376-386.
[27]
Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy[J]. N Engl J Med, 2011, 365(18): 1673-1683.
[28]
Gomes-Silva D, Srinivasan M, Sharma S, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies[J]. Blood, 2017, 130(3): 285-296.
[29]
Cooper ML, Choi J, Staser K, et al. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies[J]. Leukemia, 2018, 32(9): 1970-1983.
[30]
Png YT, Vinanica N, Kamiya T, et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies[J]. Blood Adv, 2017, 1(25): 2348-2360.
[31]
Chen KH, Wada M, Pinz KG, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor[J]. Leukemia, 2017, 31(10): 2151-2160.
[32]
You F, Wang Y, Jiang L, et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia[J]. Am J Cancer Res, 2019, 9(1): 64-78.
2022年第43卷第8期
16
5
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.08.001
  • 接收时间:2022-02-13
  • 首发时间:2026-11-19
  • 出版时间:2022-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-02-13
基金
江苏省卫生健康委员会基金项目(ZD2021006)
作者信息
    1.苏州大学附属儿童医院血液科,江苏 苏州 215002
    2.上海天泽云泰生物医药有限公司,上海 201210

通讯作者:

卢俊,主任医师,研究方向:儿童血液肿瘤。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.08.001
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏